Advertisement

Prodrugs pp 541-572 | Cite as

Prodrugs for Liver-targeted Drug Delivery

  • Mark D. Erion
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

The liver is the organ in the body primarily responsible for maintaining a continuous supply of glucose, lipids, and other important metabolic substrates to peripheral tissues (Kahl, 1999). The liver also helps to control the circulating levels of certain amino acids, ketone bodies, free fatty acids, lipoproteins, and some hormones (e.g., insulin, steroids, T3) and plays an important role in the detoxification and excretion of various xenobiotics. Chronic liver diseases such as viral hepatitis and liver cancer, as well as some metabolic diseases associated with the liver such as non-alcoholic steatohepatitis, injure the liver. Chronic liver injury can lead sequentially to impaired liver function, liver failure, and death. Drugs for treating liver diseases are often limited by tolerability and extra-hepatic safety concerns, which prevent their use at maximally effective doses. Targeting drugs to the liver may circumvent some of these limitations and enable more effective therapies. This chapter reviews the liver-targeting strategies explored to date and, more specifically, the strengths and weaknesses of various prodrug strategies used for liver-specific drug delivery.

Keywords

Bile Acid Adefovir Dipivoxil Vinyl Ketone Bile Acid Transporter Woodchuck Hepatitis Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arap W, Pasqualini R, and Ruoslahti E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in Mouse Model. Science 1998; 279:377–380PubMedCrossRefGoogle Scholar
  2. Arner ES and Eriksson S. Mammalian Deoxyribonucleoside Kinases. Pharmacol Ther 1995; 67:155–186PubMedCrossRefGoogle Scholar
  3. Beljaars A, Meijer DKF, and Pocistra K. Targeting Hepatic Stellate in Cell-specific Treatment of Liver Fibrosis. Front Biosci 2002; 7:214–222CrossRefGoogle Scholar
  4. Biessen EAL, Valentijn ARPM, De Vrueh RLA, Van De Bilt E, Sliedregt LAJM, Prince P, Bijsterbosch MK, Van Boom JH, Van Der Marel GA, Abrahams PJ, and Van Berkel TJC. Novel Hepatotrophic Prodrugs of the Antiviral Nucleoside 9-(2-Phosphonylmethoxyethyl)adenine with Improved Pharmacokinetics and Antiviral Activity. FASEB J 2000; 14:1784–1792PubMedCrossRefGoogle Scholar
  5. Bijsterbosch MK, Ying D, De Vrueh RLA, De Dlercq E, Biessen EAL, Neyts J, and Van Berkel TJC. Carrier-Mediated Delivery Improves the Efficacy of 9-(2-Phosphonylmethoxyethl) Adenine against Hepatitis B Virus. Mol Pharmacol 2001; 60:521–527PubMedGoogle Scholar
  6. Bissell DM. Cell-matrix Interaction and Hepatic Fibrosis. Prog Liver Dis 1990; 9:143–155.PubMedGoogle Scholar
  7. Camiener GW and Smith CG. Studies of the Enzymatic Deamination of Cytosine Arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol 1965; 14:1405–1416.PubMedCrossRefGoogle Scholar
  8. Chao Y-C, Lai M-Y, Chang T-T, Chuang W-L, Yang S-S, Lin C-C, Braeckman R, Chen D-S. Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Pradefovir, A Liver-Targeting Prodrug of PMEA in HBV Patients Following Daily Dosing for 28 Days. Hepatology 2004; 40:Oct. Suppl.Google Scholar
  9. Dallas S, Schlichter L, and Bendayan R. Multidrug Resistance Protein (MRP) 4-and MRP 5-Mediated Efflux of 9-(2-Phosphonylmethoxyethyl)adenine by Microglia. J Pharmacol Exp Ther 2004; 309:1221–1229PubMedCrossRefGoogle Scholar
  10. Dando T, Plosker G. Adefovir Dipivoxil: A Review of its Use in Chronic Hepatitis B. Drugs 2003; 63:2215–2234PubMedCrossRefGoogle Scholar
  11. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC A Novel Selective Broad-Spectrum Anti-DNA Virus Agent. Nature 1986; 323, 464–467PubMedCrossRefGoogle Scholar
  12. De Vrueh RLA, Rump ET, Van De Bilt E, Van Veghel R, Balzarini J, Biessen EAL, Van Berkel TJC, and Bijsterbosch MK. Carrier-Mediated Delivery of 9-(2-Phosphonylmethoxyethyl) Adenine to Parenchymal Liver Cells: A Novel Therapeutic Approach for Hepatitis B. Antimicrob Agents Chemother 2000; 44:477–483PubMedCrossRefGoogle Scholar
  13. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH. Cytochrome P450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues. J Pharmacol Exp Ther 1990; 253:387–394PubMedGoogle Scholar
  14. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, and Talalay P. Potency of Michael Reaction Acceptors as Inducers of Enzymes that Protect against Carcinogenesis Depends on their Reactivity with Sulfhydryl Groups. Proc Natl Acad Sci USA 2001; 98:3404–3409PubMedCrossRefGoogle Scholar
  15. Erion MD, Reddy KR, Boyer SH, Matelich MC, Galeno JG, Lemus RH, Ugarkar BG, Colby TJ, Schanzer J, and van Poelje PD. Design, Synthesis and Characterization of a Series of Cytochrome P450 3A-Activated Prodrugs (HepDirectℳ Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver. J Am Chem Soc 2004a; 126:5154–5163PubMedCrossRefGoogle Scholar
  16. Erion MD, van Poelje PD, MacKenna DA, Colby TJ, Montag A, Fujitaki JM, Linemeyer DL, and Bullough DA. Liver Targeted Drug Delivery Using HepDirectℳ Prodrugs. J Pharmacol Exp Ther 2004b; 308:554–560CrossRefGoogle Scholar
  17. Fiume L, Bonino F, Mattioli A, Torrani-Cerenzia MR, Busi C, Brunetto MR, Verme G, and Chiaberge E. Inhibition of Hepatitis B Virus Replication by Vidarabine Monophosphate Conjugated with Lactosaminated Serum Albumin. Lancet 1988; 13–15Google Scholar
  18. Fiume L, Di Stefano G, Busi C, Mattioli A, Bonino F, Torrani-Cerenzia M, Verme G, Papicetta M, Bertini M, and Gervasi GB. Liver Targeting of Antiviral Nucleoside Analogues through the Asialoglycoprotein Receptor. J Viral Hepatitis 1997; 4:363–370CrossRefGoogle Scholar
  19. Freeman S and Ross K. Prodrugs Design for Phosphates and Phosphonates. Prog Med Chem 1997; 32:113–147Google Scholar
  20. Ferrara E, Oishi J, Wannemacher R, and Stephens E. Plasma Disappearance, Urine Excretion and Tissue Distribution of Ribavirin in Rats and Rhesus Monkeys. Antimicrob Agents Chemother 1981; 19:1042–1049PubMedGoogle Scholar
  21. Friedman SL. The Cellular Basis of Hepatic Fibrosis: Mechanisms and Treatment Strategies. New Engl J Med 1993; 328:1828–1835PubMedCrossRefGoogle Scholar
  22. Gibbs MA and Hosea NA. Factors Affecting the Clinical Development of Cytochrome P450 3A Substrates. Clin Pharmacokinet 2003; 42:969–984PubMedCrossRefGoogle Scholar
  23. Glue P. The Clinical Pharmacology of Ribavirin. Semin Liver Dis 1999; 19:17–24PubMedGoogle Scholar
  24. Hales BF, Ludeman SM, and Boyd VL. Embryotoxicity of Phenyl Ketone Analogs of Cyclophosphamide. Teratology 1989; 39:31–37PubMedCrossRefGoogle Scholar
  25. Hostetler KY, Carson DA, and Richman DD. Phosphatidylazidothymidine. Mechanism of Antiretroviral Action in CEM Cells. J Biol Chem 1991; 266:11714–11717PubMedGoogle Scholar
  26. Hostetler KY, Korba BE, Sridhar CN, and Gardner MF. Antiviral Activity of Phosphatidyl-dideoxycytidine in Hepatitis B-infected Cells and Enhanced Hepatic Uptake in Mice. Antiviral Res 1994; 24:59–67PubMedCrossRefGoogle Scholar
  27. Hostetler KY, Beadle JR, Hornbuckle WE, Bellezza CA, Tochkov IA, Cote PJ, Gerin JL, Korba BE, and Tennant BC. Antiviral Activities of Oral 1-OHexadecylpropanediol-3-Phosphoacyclovir and Acyclovir in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob Agents Chemother 2000; 44:1964–1969PubMedCrossRefGoogle Scholar
  28. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181–182:447–452PubMedCrossRefGoogle Scholar
  29. Jones AL, Anatomy of the Normal Liver In: Zakim D and Boyer TD. Hepatology: A Textbook of Liver Disease Volume 1. Philadelphia, PA: W.B. Saunders Company; 1996:3–32Google Scholar
  30. Jonker JW and Schinkel AH. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004; 308:2–9PubMedCrossRefGoogle Scholar
  31. Kahl R. The Liver. In: Marquardt H. Toxicology. San Diego, CA: Academic Press; 1999:273–296CrossRefGoogle Scholar
  32. Katz N and Jungermann K. Metabolic Heterogeneity of the Liver. In: Tavolini N. and Berk PD. Hepatic Transport and Bile Secretion: Physiology and Pathophysiology. New York, NY: Raven Press; 1993:55–70Google Scholar
  33. Korba BA, Xie H, Wright KN, Hornbuckle WE, Gerin JL, Tennant BC, and Hostetler KY. Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo. Hepatology 1996; 23:958–963PubMedGoogle Scholar
  34. Kramer W, Wess G, Schubert G, Bickel M, Girbig F, Gutjahr U, Kowalewski S, Baringhurs KH, Enhsen A, Glombik H, Mullner S, Neckermann G, Schulz S, and Petzinger E. Liver-specific Drug Targeting by Coupling to Bile Acids. J Biol Chem 1992; 267:18598–18604PubMedGoogle Scholar
  35. Kramer W, Wess G, Enhsen A, Bock K, Falk E, Hoffman A, Neckermann G, Gantz D, Schulz S, Nickau L, Petzinger E, Turley S, and Dietschy JM. Bile Acid derived HMG-CoA reductase inhibitors. Biochim Biophys Acta 1994; 1227:137–154PubMedGoogle Scholar
  36. Krise JP and Stella VJ. Prodrugs of Phosphates, Phosophonates and Phosophinates. Adv Drug Delivery Rev 1996; 19:287–310CrossRefGoogle Scholar
  37. Kullak-Ubick GA. Regulation of organic anion and drug transporters of the sinusoidal membrane. J Hepatol 1999; 31:563–573CrossRefGoogle Scholar
  38. Kullak-Ublick GA, Beuers U, and Paumgartner G. Hepatobiliary Transport. J Hepatol 2000; 32:3–18PubMedCrossRefGoogle Scholar
  39. Kuhr T, Eisterer W, Apfelbeck U, Linkesch W, Bechter O, Zabernigg A, Geissler K, Barbieri G, Duba C, Gastl G, Thaler J. Treatment of Patients with Advanced Chronic Myelogenous Leukemia with Interferon-alpha-2b and Continuous Oral Cytarabine Ocfosfate (YNK01): A Pilot Study. Leukemia Res 2000; 24:583–587CrossRefGoogle Scholar
  40. Lewis DFV. Human Cytochromes P450 Associated with the Phase 1 Metabolism of Drugs and Other Xenobiotics: A compilation of subtrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 2003; 10:1955–1972PubMedCrossRefGoogle Scholar
  41. Lin C, Yeh LT, Vitarella D, and Hong Z. Viramidine, a Prodrug of Ribavirin, Shows Better Liver-Targeting Properties and Safety Profiles than Ribavirin in Animals. Antiviral Chem Chemother 2003; 14:145–152Google Scholar
  42. Lin C, Lourenco D, Xu G, and Yeh LT. Disposition and Metabolic Profiles of [14C]Viramidine and [14C]Ribavirin in Rat and Monkey Red Blood Cells and Liver. Antimicrob Agents Chemother 2004a; 48:1872–1875PubMedCrossRefGoogle Scholar
  43. Lin C, Yeh L-T, Vitarella D, and Erion MD. Pradefovir Mesylate: A Prodrug of PMEA with Improved Liver-Targeting and Safety in Rats and Monkeys. Antiviral Chem Chemother, 2004b; 15:307–317Google Scholar
  44. Lin JH and Lu AYH. Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes. Annu Rev Pharmacol Toxicol 2001; 41:535–567PubMedCrossRefGoogle Scholar
  45. Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. New Engl J Med 2003; 348:808–816PubMedCrossRefGoogle Scholar
  46. Meijer DKF, Jansen RW, and Molema G. Drug Targeting Systems for Antiviral Agents: Options and Limitations. Antiviral Res 1992; 18:215–258PubMedCrossRefGoogle Scholar
  47. Meijer DKF and Molema G. Targeting of Drugs to the Liver. Semin Liver Dis 1995; 15:202–256PubMedCrossRefGoogle Scholar
  48. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, and Brodie BB. Acetaminopheninduced Hepatic Necrosis. IV. Protective role of Glutathione. J Pharmacol Exp Ther 1973; 187:211–217PubMedGoogle Scholar
  49. Neudecker T, Eder E, Deininger C, Hoffman C, and Henschler D. Mutagenicity of Methylvinyl Ketone in Salmonella typhimurium TA100—Indication for Epoxidation as an Activation Mechanism. Mutat Res 1989; 227:131–134PubMedCrossRefGoogle Scholar
  50. Petzinger E, Nickau L, Horz JA, Schulz S, Wess G, Enissen A, Falk E, Baringhaus KH, Glombik H, Hoffman A, Mullner S, Neckermann G, and Kramer W. Hepatobiliary Transport of Hepatic 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors Conjugated With Bile Acids. Hepatology 1995; 22:1801–1811PubMedGoogle Scholar
  51. Ruoslahti E. Drug targeting to Specific Vascular Sites. Drug Discov Today 2002; 7: article 22:1138–1143PubMedCrossRefGoogle Scholar
  52. Schultz C. Prodrugs of Biologically Active Phosphate Esters. Bioorg Med Chem 2003; 11:885–898PubMedCrossRefGoogle Scholar
  53. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich P. Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Therap 1994; 270:414–423Google Scholar
  54. Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, Miwa M, Ura M, Sawada N, Tahara H, Kuruma I, Horii I, and Ishitsuka H. The Design and Synthesis of a New Tumor-Selective Fluoropyrimidine Carbamate, Capecitabine. Bioorg Med Chem 2000; 8:1697–1706PubMedCrossRefGoogle Scholar
  55. Stella VJ and Himmelstein KJ. Prodrugs and Site-Specific Drug Delivery. J Med Chem 1980; 23:1275–1282PubMedCrossRefGoogle Scholar
  56. Stephan ZF, Yurachek EC, Sharif R, Wasvary JM, Steele RE, and Howes C. Reduction of Cardioascular and Thyroxine-suppressing Activities of L-T3 by Liver Targeting with Cholic Acid. Biochem Pharmacol 1992; 43:1969–1974PubMedCrossRefGoogle Scholar
  57. Stockert RJ. The Asialoglycoprotein Receptor: Relationships Between Structure, Function, and Expression. Physiol Rev 1995; 75:591–609PubMedGoogle Scholar
  58. Suriawinata, A and Fiel MI. Liver Pathology and Obesity. Semin Liver Dis 2004; 24:363–370PubMedCrossRefGoogle Scholar
  59. Suto T, Miyazawa J, Watanabe Y, Suto K, Yoshida Y, and Sakata Y. The Effect of YNK-01 (an Oral Prodrug of Cytarabine) on Hepatocellular Carcinoma. Semin in Oncology 1997; 24:S6-122–S6-129Google Scholar
  60. Tomlinson E. Theory and Practice of Site-specific Drug Delivery. Adv Drug Delivery Rev 1987; 1:87–198CrossRefGoogle Scholar
  61. Tomlinson E. Site-Specific Drugs and Delivery Systems: Rationale, Potential and Limitations. Trends Drug Res 1990; 13:287–302Google Scholar
  62. Van Der Weyden MB and Kelley WN. Human Adenosine Deaminase. J Biol Chem 1976; 251:5448–5456PubMedGoogle Scholar
  63. Van Montfoort JE, Hagenbuch B, Groothuis GMM, Koepsell H, Meier PJ, and Meijer DKF. Drug Uptake Systems in Liver and Kidney. Curr Drug Metab 2003; 4:185–211PubMedCrossRefGoogle Scholar
  64. Villeneuve J-P and Pichette V. Cytochrome P450 and Liver Diseases. Curr Drug Metab 2004; 5:273–282PubMedCrossRefGoogle Scholar
  65. Wu J, Nantz MH, and Zern MA. Targeting Hepatocytes for Drug and Dene delivery: Emerging Novel Approaches and Applications. Front Biosci 2002; 7:717–725CrossRefGoogle Scholar
  66. Wu JZ, Lin C, and Hong Z. Ribavirin, Viramidine and Adenosine-deaminasecatalysed Drug Activation: Implication for Nucleoside Prodrug Design. J Antimicrob Chemother 2003; 52:543–546PubMedCrossRefGoogle Scholar
  67. Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ. Metabolic sSudies on BMS-200475, A New Antiviral Compound Active against Hepatitis B Virus. Antimicrob Agents Chemother 1999; 43:190–193PubMedGoogle Scholar
  68. Yoshida Y, Yamada J, Watanabe T, Suga T, Takayama H. Participation of the Peroxisomal Beta-oxidation System in the Chain-shortening of PCA16, a Metabolite of the Cytosine Arabinoside Prodrug, YNKO1, in Rat Liver. Biochem Pharmacol 1990; 39:1505–1512PubMedCrossRefGoogle Scholar
  69. Zhang YJ, Chen S, Tsai WY, Ahsan H, Lunn RM, Wang LY, Chen CJ, and Santella RM. Expression of Cytochrome P450 1A1/2 and 3A4 in Liver Tissues of Hepatocellular Carcinoma Cases and Controls from Taiwan and their Relationship to Hepatitis B Virus and Aflatoxin B1-and 4-Aminobiphenyl-DNA Adducts. Biomarkers 2000; 5:295–306CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Mark D. Erion
    • 1
  1. 1.Metabasis Therapeutics, Inc.La Jolla

Personalised recommendations